 Wendy Bamberg
Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 16 | 2021 | 263 | 1.840 |
Why?
| | beta-Lactamases | 7 | 2022 | 52 | 1.670 |
Why?
| | Carbapenems | 7 | 2022 | 27 | 1.520 |
Why?
| | Disease Outbreaks | 5 | 2019 | 423 | 0.830 |
Why?
| | Enterobacteriaceae | 4 | 2022 | 44 | 0.760 |
Why?
| | Candidemia | 2 | 2020 | 15 | 0.750 |
Why?
| | Clostridium Infections | 6 | 2021 | 74 | 0.740 |
Why?
| | Acinetobacter baumannii | 2 | 2018 | 26 | 0.690 |
Why?
| | Substance Abuse, Intravenous | 2 | 2019 | 127 | 0.640 |
Why?
| | Candida | 2 | 2020 | 45 | 0.610 |
Why?
| | Klebsiella Infections | 2 | 2022 | 26 | 0.590 |
Why?
| | Antimicrobial Stewardship | 4 | 2021 | 129 | 0.560 |
Why?
| | Enterobacteriaceae Infections | 4 | 2022 | 42 | 0.520 |
Why?
| | Anti-Bacterial Agents | 10 | 2022 | 1928 | 0.520 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 5 | 2018 | 248 | 0.500 |
Why?
| | Streptococcus | 1 | 2016 | 29 | 0.480 |
Why?
| | Population Surveillance | 8 | 2020 | 484 | 0.470 |
Why?
| | Staphylococcal Infections | 5 | 2018 | 388 | 0.460 |
Why?
| | Klebsiella pneumoniae | 2 | 2022 | 47 | 0.450 |
Why?
| | Nursing Homes | 4 | 2021 | 173 | 0.440 |
Why?
| | Bacterial Proteins | 3 | 2018 | 981 | 0.430 |
Why?
| | Infection Control | 1 | 2016 | 174 | 0.420 |
Why?
| | Colorado | 10 | 2021 | 4558 | 0.410 |
Why?
| | Streptococcal Infections | 1 | 2016 | 170 | 0.400 |
Why?
| | Drug Resistance, Bacterial | 4 | 2018 | 205 | 0.340 |
Why?
| | Community-Acquired Infections | 5 | 2021 | 175 | 0.330 |
Why?
| | Bacteremia | 3 | 2019 | 222 | 0.300 |
Why?
| | Microbial Sensitivity Tests | 4 | 2022 | 373 | 0.300 |
Why?
| | Acinetobacter Infections | 2 | 2018 | 15 | 0.280 |
Why?
| | Anti-Infective Agents | 2 | 2021 | 242 | 0.280 |
Why?
| | beta-Lactam Resistance | 2 | 2018 | 10 | 0.260 |
Why?
| | Goat Diseases | 1 | 2007 | 1 | 0.250 |
Why?
| | Coxiella burnetii | 1 | 2007 | 2 | 0.250 |
Why?
| | Q Fever | 1 | 2007 | 5 | 0.250 |
Why?
| | Risk Factors | 11 | 2022 | 10796 | 0.250 |
Why?
| | Catheter-Related Infections | 4 | 2015 | 95 | 0.240 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 171 | 0.240 |
Why?
| | Hospitals | 4 | 2021 | 729 | 0.240 |
Why?
| | Incidence | 12 | 2020 | 2892 | 0.240 |
Why?
| | Sepsis | 3 | 2020 | 643 | 0.230 |
Why?
| | Outpatients | 3 | 2019 | 447 | 0.220 |
Why?
| | Drug Utilization | 3 | 2021 | 167 | 0.220 |
Why?
| | Middle Aged | 18 | 2021 | 35971 | 0.210 |
Why?
| | Aged, 80 and over | 10 | 2021 | 8284 | 0.210 |
Why?
| | Aged | 17 | 2021 | 25955 | 0.200 |
Why?
| | Urinary Tract Infections | 3 | 2021 | 206 | 0.190 |
Why?
| | United States | 19 | 2022 | 16018 | 0.180 |
Why?
| | Adult | 16 | 2021 | 40489 | 0.180 |
Why?
| | Homes for the Aged | 2 | 2019 | 32 | 0.180 |
Why?
| | Young Adult | 9 | 2021 | 14122 | 0.170 |
Why?
| | Humans | 36 | 2022 | 144667 | 0.170 |
Why?
| | Escherichia coli Infections | 1 | 2022 | 126 | 0.170 |
Why?
| | Long-Term Care | 2 | 2018 | 117 | 0.160 |
Why?
| | Nursing Care | 1 | 2020 | 38 | 0.150 |
Why?
| | Serratia Infections | 1 | 2019 | 8 | 0.150 |
Why?
| | Serratia marcescens | 1 | 2019 | 17 | 0.150 |
Why?
| | Syringes | 1 | 2019 | 49 | 0.140 |
Why?
| | Equipment Contamination | 1 | 2019 | 71 | 0.140 |
Why?
| | Child Day Care Centers | 1 | 2019 | 44 | 0.140 |
Why?
| | Male | 20 | 2021 | 72431 | 0.140 |
Why?
| | Food Microbiology | 1 | 2019 | 73 | 0.140 |
Why?
| | Shock, Septic | 1 | 2020 | 216 | 0.140 |
Why?
| | Residential Facilities | 1 | 2018 | 8 | 0.140 |
Why?
| | Female | 20 | 2022 | 78304 | 0.130 |
Why?
| | Child, Preschool | 11 | 2021 | 11790 | 0.130 |
Why?
| | Ambulatory Care Facilities | 2 | 2016 | 267 | 0.120 |
Why?
| | Hospitalization | 4 | 2020 | 2446 | 0.120 |
Why?
| | Inpatients | 1 | 2021 | 547 | 0.120 |
Why?
| | Travel | 1 | 2016 | 136 | 0.110 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 39 | 0.110 |
Why?
| | Health Status Disparities | 1 | 2018 | 318 | 0.110 |
Why?
| | Epidemiologic Methods | 1 | 2015 | 89 | 0.110 |
Why?
| | Infant | 10 | 2021 | 10023 | 0.110 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2013 | 39 | 0.100 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2013 | 28 | 0.100 |
Why?
| | Catheterization, Central Venous | 1 | 2015 | 124 | 0.100 |
Why?
| | Renal Dialysis | 2 | 2015 | 465 | 0.090 |
Why?
| | Child | 11 | 2021 | 22600 | 0.090 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2013 | 104 | 0.090 |
Why?
| | Central Venous Catheters | 1 | 2013 | 52 | 0.090 |
Why?
| | Prevalence | 4 | 2021 | 2839 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 1360 | 0.090 |
Why?
| | Adolescent | 10 | 2021 | 22409 | 0.090 |
Why?
| | Risk Assessment | 1 | 2021 | 3729 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2015 | 586 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2013 | 537 | 0.080 |
Why?
| | Mental Disorders | 1 | 2020 | 1154 | 0.080 |
Why?
| | Sequence Analysis, DNA | 1 | 2014 | 828 | 0.080 |
Why?
| | Environmental Microbiology | 2 | 2008 | 57 | 0.080 |
Why?
| | Infant, Newborn | 5 | 2021 | 6399 | 0.070 |
Why?
| | Salmonella Food Poisoning | 1 | 2008 | 12 | 0.070 |
Why?
| | Salmonella | 1 | 2008 | 61 | 0.070 |
Why?
| | Wounds and Injuries | 1 | 2016 | 960 | 0.070 |
Why?
| | Goats | 1 | 2007 | 18 | 0.060 |
Why?
| | Regression Analysis | 2 | 2018 | 998 | 0.060 |
Why?
| | Antibodies, Bacterial | 1 | 2007 | 146 | 0.060 |
Why?
| | Horses | 1 | 2007 | 203 | 0.060 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2008 | 287 | 0.060 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 2 | 2015 | 23 | 0.050 |
Why?
| | Age Distribution | 2 | 2015 | 402 | 0.050 |
Why?
| | Sex Distribution | 2 | 2015 | 386 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1537 | 0.050 |
Why?
| | Health Facilities | 1 | 2022 | 86 | 0.040 |
Why?
| | Prescription Drug Overuse | 1 | 2021 | 10 | 0.040 |
Why?
| | Tennessee | 1 | 2021 | 56 | 0.040 |
Why?
| | Fluoroquinolones | 1 | 2021 | 45 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2021 | 17149 | 0.040 |
Why?
| | Causality | 1 | 2020 | 126 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5870 | 0.040 |
Why?
| | Hospital Bed Capacity | 1 | 2018 | 28 | 0.040 |
Why?
| | Hospital Units | 1 | 2018 | 32 | 0.040 |
Why?
| | Epidemiological Monitoring | 1 | 2018 | 69 | 0.030 |
Why?
| | Documentation | 1 | 2020 | 198 | 0.030 |
Why?
| | Heparin | 1 | 2019 | 243 | 0.030 |
Why?
| | Catheterization | 1 | 2018 | 183 | 0.030 |
Why?
| | Feces | 2 | 2013 | 513 | 0.030 |
Why?
| | Escherichia coli | 1 | 2022 | 854 | 0.030 |
Why?
| | History, 21st Century | 1 | 2018 | 220 | 0.030 |
Why?
| | Skilled Nursing Facilities | 1 | 2018 | 151 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2114 | 0.030 |
Why?
| | Oregon | 1 | 2015 | 76 | 0.030 |
Why?
| | Public Health | 1 | 2021 | 569 | 0.030 |
Why?
| | Sentinel Surveillance | 1 | 2015 | 46 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2020 | 574 | 0.030 |
Why?
| | Georgia | 1 | 2015 | 79 | 0.030 |
Why?
| | Maryland | 1 | 2015 | 67 | 0.030 |
Why?
| | New Mexico | 1 | 2015 | 99 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 557 | 0.030 |
Why?
| | New York | 1 | 2015 | 127 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2020 | 1033 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2015 | 83 | 0.030 |
Why?
| | Minnesota | 1 | 2015 | 170 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 2018 | 330 | 0.030 |
Why?
| | Bacterial Typing Techniques | 1 | 2015 | 44 | 0.030 |
Why?
| | Communicable Disease Control | 1 | 2015 | 86 | 0.030 |
Why?
| | Diagnostic Tests, Routine | 1 | 2015 | 107 | 0.030 |
Why?
| | Hospitals, Special | 1 | 2014 | 8 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 677 | 0.030 |
Why?
| | Molecular Typing | 1 | 2013 | 21 | 0.020 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2014 | 58 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2018 | 710 | 0.020 |
Why?
| | Histamine H2 Antagonists | 1 | 2013 | 23 | 0.020 |
Why?
| | Pneumonia | 1 | 2018 | 629 | 0.020 |
Why?
| | Proton Pump Inhibitors | 1 | 2013 | 109 | 0.020 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 113 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1136 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 635 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3603 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5957 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 834 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2013 | 607 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1995 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 6041 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 3147 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2014 | 944 | 0.020 |
Why?
| | Animals | 1 | 2007 | 37948 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 7994 | 0.010 |
Why?
| | Health Personnel | 1 | 2008 | 746 | 0.010 |
Why?
| | Time Factors | 1 | 2013 | 7140 | 0.010 |
Why?
|
|
Bamberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|